Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase Ib/II study TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau...
Hence then, the article about eisai presents new data on anti tau antibody etalanetug e2814 at ctad 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 )
Also on site :
- Sacramento's I Street bridge project clears major financial hurdle, bids for construction open in 1 month
- Is Luke Thompson Returning to ‘Bridgerton’ Season 5? Star Breaks Silence on Benedict’s Future (Exclusive)
- Trip.com Partners with JR Companies to Offer Nationwide Shinkansen Tickets to International Travellers